Copyright
©The Author(s) 2022.
World J Transplant. Nov 18, 2022; 12(11): 331-346
Published online Nov 18, 2022. doi: 10.5500/wjt.v12.i11.331
Published online Nov 18, 2022. doi: 10.5500/wjt.v12.i11.331
Table 3 Clinical trials assessing immune checkpoint inhibitor use in the neoadjuvant setting prior to liver resection in patients with hepatocellular carcinoma
| Trial name | Phase | Intervention | Status |
| NCT03510871 | II | Nivolumab and ipilimumab (single-arm study) | Not yet completed; estimated completion date: December 2022 |
| NCT03682276 | I/II | Nivolumab and ipilimumab (single-arm study) | Not yet completed; estimated completion date: September 2022 |
| NCT03299946 | I | Nivolumab and cabozantinib (single-arm study) | Completed |
| NCT04615143 | II | Tislelizumab or tislelizumab and Lenvatinib (sequential assignment) | Not yet completed; estimated completion date: December 2025 |
| NCT03916627 | II | Cemiplimab (parallel assignment) | Not yet completed; estimated completion date: September 2029 |
| NCT03867370 | I/II | Toripalimab or toripalimab and Lenvatinib (sequential assignment) | Not yet completed; estimated completion date: October 2022 |
| NCT03630640 | II | Nivolumab (single-arm study) | Not yet completed; estimated completion date: November 2023 |
| NCT04123379 | II | Nivolumab vs nivolumab and CCR2/5 inhibitor vs nivolumab and anti-IL-8 antibody (parallel assignment) | Not yet completed; estimated completion date: October 2024 |
| NCT04297202 | II | SHR-1210 (anti-PD1 inhibitor) and apatinib (single-arm study) | Completed |
- Citation: Ouranos K, Chatziioannou A, Goulis I, Sinakos E. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World J Transplant 2022; 12(11): 331-346
- URL: https://www.wjgnet.com/2220-3230/full/v12/i11/331.htm
- DOI: https://dx.doi.org/10.5500/wjt.v12.i11.331